Pharmaceuticals, Biotechnology and Life Sciences
– Company granted 180 days of exclusivity under FDA Competitive Generic Therapy approval pathway – BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc.…
Colorado BioScience Association connects health innovators to investors during biennial event VAIL, Colo.–(BUSINESS WIRE)–#RockyMtnBioInvest—Colorado BioScience Association (CBSA) welcomes investors and…
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at…
Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.
Velesco Pharma, is expanding its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, Michigan, the company said Wednesday in a press release.
Pacific Biosciences’ Single Molecule, Real-Time Sequencing technology has been selected by the European research program SOLVE-RD to help reveal the genetic mechanisms responsible for rare genetic diseases. As part of this work, scientists will sequence more than 500 whole human genomes with the PacBio Sequel II System to pinpoint disease-causing variants.
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, has started dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in patients with Parkinson’s disease, and the launch of its Engage Parkinson’s website.
Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments, along with patient survey results and post hoc efficacy results following the 1-year Phase III HALO long-term study
MADISON, Wis.–(BUSINESS WIRE)–#mentalhealth—Usona Institute launches its Phase 2 study of psilocybin for major depressive disorder this fall. The study, PSIL201,…
Addition of clinical research sites advances AES’ strategy of becoming the world’s largest patient access and site conduct organization WILMINGTON,…